Results 181 to 190 of about 4,279 (197)

French national cohort of first use of dalbavancin: A high proportion of off-label use

International Journal of Antimicrobial Agents, 2019
Aurélien Dinh, Clara Duran, Alexandre Bleibtreu   +2 more
exaly  

Dalbavancin

2017
openaire   +1 more source

Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections

Antimicrobial Agents and Chemotherapy, 2019
Alicia Rico
exaly  

Dalbavancin use in an academic medical centre and associated cost savings

International Journal of Antimicrobial Agents, 2019
Amber Streifel, Christina D Bowen
exaly  

Dalbavancin as Secondary Therapy for Serious Staphylococcus aureus Infections in a Vulnerable Patient Population

Open Forum Infectious Diseases, 2019
Chloe Bryson-Cahn, Alison M Beieler, Shireesha Dhanireddy   +2 more
exaly  

Dalbavancin/vancomycin

Reactions Weekly, 2022
openaire   +1 more source

Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection

New England Journal of Medicine, 2014
exaly  

Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci

Diagnostic Microbiology and Infectious Disease, 2018
Robin Patel
exaly  

Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen

Clinical Microbiology and Infection, 2018
exaly  

Dalbavancin

2016
openaire   +1 more source